Advertisement

Chronic Graft-Versus-Host Disease

  • H. Joachim Deeg
  • Hans-Georg Klingemann
  • Gordon L. Phillips

Abstract

Chronic GVHD typically develops >3 months post-transplant, although histologic and clinical manifestations can be present earlier. Chronic GVHD differs from acute GVHD in its distribution of target organs and clinical presentation. T-lymphocytes are likely involved in the pathogenesis of both types, but in contrast to acute GVHD, in which T-cells respond to alloantigens, T-cells in chronic GVHD react in an autoimmune fashion against histocompatibility alloantigens of the host (public determinant of MHC class II molecules). These T-cells produce abnormal patterns of cytokines and can stimulate the production of collagen by fibroblasts. In long-term stable survivors without chronic GVHD, alloimmunity seems to be blocked by specific suppressor cells which usually are not found in patients with chronic GVHD. It has also been postulated that the establishment of tolerance requires a functioning thymus. Since thymus function can be impaired as a consequence of chemo/radiotherapy or acute GVHD, the lack of thymus function may hamper the development of specific suppressor cells capable of mediating stable graft-host tolerance, and/or delete autoreactive T-cells. The donor-host directed alloaggression may be only an initial event leading to autoimmune symptoms, impaired immune reconstitution and infections and it is likely that the release of certain cytokines contributes to the manifestation of chronic GVHD.

Keywords

Acute GVHD Chronic GVHD Chronic Graft Sicca Syndrome Thymus Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Atkinson K, Bryant D, Delprado W, Biggs J (1989) Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-versus-host disease. Bone Marrow Transplant 4:129PubMedGoogle Scholar
  2. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM (1989) Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 4:247PubMedGoogle Scholar
  3. Corson SL, Sullivan K, Batzer F, August C, Storb R, Thomas ED (1982) Gynecologic manifestations of chronic graft-versus-host disease. Obstet Gynecol 60:488PubMedGoogle Scholar
  4. Ferrara JLM, Deeg HJ (1991) Graft-versus-host disease. N Engl J Med 324:667PubMedCrossRefGoogle Scholar
  5. Franklin RM, Kenyon KR, Tutschka PJ, Saral R, Green WR, Santos G (1983) Ocular manifestations of chronic graft-versus-host disease. Ophthalmology 90:4PubMedGoogle Scholar
  6. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW (1988) Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood 72:621PubMedGoogle Scholar
  7. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555PubMedGoogle Scholar
  8. Kalhs P, Panzer S, Kletter K, Minar E, Stain-Kos M, Walter R, Lechner K, Hinterberger W (1988) Functional asplenia after bone marrow transplantation: A late complication related to extensive chronic graft-versus-host disease. Ann Intern Med 109:461PubMedGoogle Scholar
  9. Klingemann H-G, Phillips GL (1991) Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 8:73PubMedGoogle Scholar
  10. Loughran Jr TP, Sullivan K, Morton T, Beckham C, Schubert M, Witherspoon R, Sale G, Sanders J, Fisher L, Shulman H, Thomas ED, Storb R (1990) Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76:228PubMedGoogle Scholar
  11. Lum LG (1987) The kinetics of immune reconstitution after human marrow transplantation. Blood 69:369PubMedGoogle Scholar
  12. McDonald GB, Sullivan KM, Plumley TF (1984) Radiographic features of esophageal involvement in chronic graft-vs-host disease. AJR Am J Roentgenol 142:501PubMedGoogle Scholar
  13. Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A (1987) Autoimmunity in 28 patients after allogeneic bone marrow transplantation: Comparison with Sjogren syndrome and scleroderma. Br J Haematol 66:45PubMedGoogle Scholar
  14. Sale GE, Shulmann HM, Schubert MM, Sullivan KM, Kopecky KJ, Hackman RC, Morton TH, Storb R, Thomas ED (1981) Oral and ophthalmic pathology of graft-versus-host disease in man: Predictive value of the lip biopsy. Hum Pathol 12:1022PubMedCrossRefGoogle Scholar
  15. Schubert HM, Sullivan KM, Morton TH, Izutsu KT, Peterson DE, Flournoy N, Truelove EL, Sale GE, Buckner CD, Storb R, Thomas ED (1984) Oral manifestation of chronic graft versus host disease. Ann Intern Med 144:1591CrossRefGoogle Scholar
  16. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA (1990) Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 75:1583PubMedGoogle Scholar
  17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman RC, Tsoi MD, Storb R, Thomas ED (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204PubMedCrossRefGoogle Scholar
  18. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED (1981) Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 57:267PubMedGoogle Scholar
  19. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, Loughran TP, Hill R, Shields A, Yee G, Shulman H, Nims J, Strom S, Thomas ED (1988) Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72:555PubMedGoogle Scholar
  20. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR, McGuffin R, McDonald GB, Meyers J, Schubert MM, Gauvreau J, Shulman HM, Sale GE, Anasetti C, Loughran TP, Strom S, Nims J, Thomas ED (1988) Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72:546PubMedGoogle Scholar
  21. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720PubMedGoogle Scholar
  22. Tanaka K, Sullivan KM, Shulman HM, Sale GE, Tanaka A (1991) A clinical review: Cutaneous manifestations of acute and chronic graft-versus-host disease following bone marrow transplantation. J Dermatol 18:11PubMedGoogle Scholar
  23. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981) Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529PubMedCrossRefGoogle Scholar
  24. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin S, Beschorner WE, Cahill RA, Miller DF, Harrison D, Saral R, Santos GW (1989) Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74:1428PubMedGoogle Scholar
  25. Wood PMD, Proctor SJ (1990) The potential use of thalidomide in the therapy of graft-versus-host disease — a review of clinical and laboratory information. Leuk Res 14:395PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. Joachim Deeg
    • 1
  • Hans-Georg Klingemann
    • 2
  • Gordon L. Phillips
    • 3
  1. 1.Clinical Research DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Department of MedicineThe University of British ColumbiaVancouverCanada
  3. 3.Division of HematologyThe University of British ColumbiaVancouverCanada

Personalised recommendations